Satyesh K Sinha1,2,3,4, Aika Miikeda1,2,3, Zachary Fouladian1,2,3, Margarete Mehrabian1,2,3, Chantle Edillor1,2,3, Diana Shih1,2,3, Zhiqiang Zhou1,2,3, Manash K Paul3, Sarada Charugundla1,2,3, Richard C Davis1,2,3, Tripathi B Rajavashisth1,2,3,4,5, Aldons J Lusis1,2,3. 1. Department of Microbiology, Immunology, and Molecular Genetics (S.K.S., A.M., Z.F., M.M., C.E., D.S., Z.Z., S.C., R.C.D., T.B.R., A.J.L.), University of California, Los Angeles. 2. Department of Medicine (S.K.S., A.M., Z.F., M.M., C.E., D.S., Z.Z., S.C., R.C.D., T.B.R., A.J.L.), University of California, Los Angeles. 3. Department of Human Genetics (S.K.S., A.M., Z.F., M.M., C.E., D.S., Z.Z., M.K.P., S.C., R.C.D., T.B.R., A.J.L.), University of California, Los Angeles. 4. Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA (S.K.S., T.B.R.). 5. Molecular Biology Unit, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India (T.B.R.).
Abstract
OBJECTIVE: Previous studies have shown that deficiency of M-CSF (macrophage colony-stimulating factor; or CSF1 [colony stimulating factor 1]) dramatically reduces atherosclerosis in hyperlipidemic mice. We characterize the underlying mechanism and investigate the relevant sources of CSF1 in lesions. Approach and Results: We quantitatively assessed the effects of CSF1 deficiency on macrophage proliferation and apoptosis in atherosclerotic lesions. Staining of aortic lesions with markers of proliferation, Ki-67 and bromodeoxyuridine, revealed around 40% reduction in CSF1 heterozygous (Csf1+/-) as compared with WT (wild type; Csf1+/+) mice. Similarly, staining with a marker of apoptosis, activated caspase-3, revealed a 3-fold increase in apoptotic cells in Csf1+/- mice. Next, we determined the cellular sources of CSF1 contributing to lesion development. Cell-specific deletions of Csf1 in smooth muscle cells using SM22α-Cre (smooth muscle protein 22-alpha-Cre) reduced lesions by about 40%, and in endothelial cells, deletions with Cdh5-Cre (VE-cadherin-Cre) reduced lesions by about 30%. Macrophage-specific deletion with LysM-Cre (lysozyme M-Cre), on the other hand, did not significantly reduce lesions size. Transplantation of Csf1 null (Csf1-/-) mice bone marrow into Csf1+/+ mice reduced lesions by about 35%, suggesting that CSF1 from hematopoietic cells other than macrophages contributes to atherosclerosis. None of the cell-specific knockouts affected circulating CSF1 levels, and only the smooth muscle cell deletions had any effect on the percentage monocytes in the circulation. Also, Csf1+/- mice did not exhibit significant differences in Ly6Chigh/Ly6Clow monocytes as compared with Csf1+/+. CONCLUSIONS: CSF1 contributes to both macrophage proliferation and survival in lesions. Local CSF1 production by smooth muscle cell and endothelial cell rather than circulating CSF1 is the primary driver of macrophage expansion in atherosclerosis.
OBJECTIVE: Previous studies have shown that deficiency of M-CSF (macrophage colony-stimulating factor; or CSF1 [colony stimulating factor 1]) dramatically reduces atherosclerosis in hyperlipidemic mice. We characterize the underlying mechanism and investigate the relevant sources of CSF1 in lesions. Approach and Results: We quantitatively assessed the effects of CSF1 deficiency on macrophage proliferation and apoptosis in atherosclerotic lesions. Staining of aortic lesions with markers of proliferation, Ki-67 and bromodeoxyuridine, revealed around 40% reduction in CSF1 heterozygous (Csf1+/-) as compared with WT (wild type; Csf1+/+) mice. Similarly, staining with a marker of apoptosis, activated caspase-3, revealed a 3-fold increase in apoptotic cells in Csf1+/- mice. Next, we determined the cellular sources of CSF1 contributing to lesion development. Cell-specific deletions of Csf1 in smooth muscle cells using SM22α-Cre (smooth muscle protein 22-alpha-Cre) reduced lesions by about 40%, and in endothelial cells, deletions with Cdh5-Cre (VE-cadherin-Cre) reduced lesions by about 30%. Macrophage-specific deletion with LysM-Cre (lysozyme M-Cre), on the other hand, did not significantly reduce lesions size. Transplantation of Csf1 null (Csf1-/-) mice bone marrow into Csf1+/+ mice reduced lesions by about 35%, suggesting that CSF1 from hematopoietic cells other than macrophages contributes to atherosclerosis. None of the cell-specific knockouts affected circulating CSF1 levels, and only the smooth muscle cell deletions had any effect on the percentage monocytes in the circulation. Also, Csf1+/- mice did not exhibit significant differences in Ly6Chigh/Ly6Clow monocytes as compared with Csf1+/+. CONCLUSIONS: CSF1 contributes to both macrophage proliferation and survival in lesions. Local CSF1 production by smooth muscle cell and endothelial cell rather than circulating CSF1 is the primary driver of macrophage expansion in atherosclerosis.
Authors: Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko Journal: J Clin Invest Date: 2016-07-11 Impact factor: 14.808
Authors: Marta Roche-Molina; David Sanz-Rosa; Francisco M Cruz; Jaime García-Prieto; Sergio López; Rocío Abia; Francisco J G Muriana; Valentín Fuster; Borja Ibáñez; Juan A Bernal Journal: Arterioscler Thromb Vasc Biol Date: 2014-10-23 Impact factor: 8.311
Authors: Christopher Tay; Peter Kanellakis; Hamid Hosseini; Anh Cao; Ban-Hock Toh; Alex Bobik; Tin Kyaw Journal: Front Immunol Date: 2020-01-10 Impact factor: 7.561
Authors: Brennan D Gerlach; Patrick B Ampomah; Arif Yurdagul; Chuang Liu; Max C Lauring; Xiaobo Wang; Canan Kasikara; Na Kong; Jinjun Shi; Wei Tao; Ira Tabas Journal: Cell Metab Date: 2021-11-15 Impact factor: 27.287
Authors: Carmen Härdtner; Jan Kornemann; Katja Krebs; Carolin A Ehlert; Alina Jander; Jiadai Zou; Christopher Starz; Simon Rauterberg; Diana Sharipova; Bianca Dufner; Natalie Hoppe; Tsai-Sang Dederichs; Florian Willecke; Peter Stachon; Timo Heidt; Dennis Wolf; Constantin von Zur Mühlen; Josef Madl; Peter Kohl; Rafael Kaeser; Tobias Boettler; Elsbeth J Pieterman; Hans M G Princen; Benoît Ho-Tin-Noé; Filip K Swirski; Clinton S Robbins; Christoph Bode; Andreas Zirlik; Ingo Hilgendorf Journal: Basic Res Cardiol Date: 2020-12-09 Impact factor: 17.165